Study Title
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer (KEVLARx)
Purpose
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers. All patients in this study will receive 7 weeks of standard of care radiation therapy given with the chemotherapy agent, cisplatin. Patients will receive RRx-001 or placebo before start of standard of care treatment.
For more information please visit https://clinicaltrials.gov/study/NCT05966194
Interested in Volunteering for the Study?
If you would like more information about this study, please call us at 318-212-8671.
Eligibility
Study Process
Trial Details
Investigator:
IRB:
** WK New Format
IRB Number:
Trial Type:
Device
Sponsor:
** WK New Format
Contact Information: